Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National Medical Products Administration (NMPA) to test its Category 1 biologic product, ZG005, in combination with gecaicitinib for the treatment of advanced solid tumors and recurrent refractory lymphomas in China.
ZG005: A Pioneering Bispecific Antibody for Solid Tumors
ZG005 is a bispecific antibody (BsAb) targeting programmed-death 1 (PD-1) and T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and is anticipated to treat a range of solid tumors. This innovative product has no equivalent approved globally, making it a potentially groundbreaking therapy in the oncology space.
Gecacitinib: A Novel JAK/ACVR1 Dual Inhibitor
Gecacitinib, the other component of the combination therapy, is a novel JAK/ACVR1 dual inhibitor currently under investigation for immune-inflammatory diseases and fibrotic diseases. It is in various stages of clinical trials, including Phase III for moderate to severe atopic dermatitis and ankylosing spondylitis, and Phase II for moderate to severe plaque psoriasis. The Category 1 product is also awaiting regulatory decisions in China for the treatment of medium-to high-risk myelofibrosis.-Fineline Info & Tech
